Skip to main content
SpringerLink
Log in

Epoetin-alfa costs less than darbepoetin-alfa in hospitalised patients, and may provide hospitals with a better option for managing pharmacy expenses,

  • Media release
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

REFERENCE

  1. Ortho Biotech Products L.P.Study Evaluates Real-World Dosing and Cost Considerations for PROCRIT(R) (Epoetin Alfa) and Darbepoetin Alfa in the Inpatient Hospital Setting. Media Release: 26 Oct 2006. Available from: URL: http://www.orthobiotech.com

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Epoetin-alfa costs less than darbepoetin-alfa in hospitalised patients, and may provide hospitals with a better option for managing pharmacy expenses,. Pharmacoecon. Outcomes News 517, 8 (2006). https://doi.org/10.2165/00151234-200605170-00021

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00151234-200605170-00021

Keywords

Search

Navigation